Pesticidas y frutas


 

borinot-mseguid.blogspot.com.es

Las manzana siguen siendo la fruta más “sucia” en EEUUA veces hay noticias que sorprenden pero al mismo tiempo te hacen pensar.Al parecer en USA existe un organismo  Environmental Working Group (EWG) que desde hace 8 años se dedica a analizar las frutas y verduras que comen en EEUU y determinar la cantidad de pesticidas que estas contienen. Esto no sería noticia si no se publicasen los resultado. Sin embargo, esta web publica una lista de las doce frutas/verduras más sucias ‘Dirty Dozen’ y las quince más limpias “Clean Fifteen”. Lo sorprendente es que no hayan importantes variaciones según los años… Leer más “Pesticidas y frutas”

Coca-cola y Pepsi cambian su composición por un posible cancerígeno

California ha dictaminado que contienen un colorante cancerígeno en ratas
La Agencia Europea de Seguridad Alimentaria considera que faltan ensayos
Diario El país http://sociedad.elpais.com

Mejor prevenir. Y si es con un producto cuyo único cometido es dar color, mejor. Es lo que han pensado los fabricantes de bebidas Coca-cola y Pepsi, que han decidido cambiar la composición de sus productos ante la sospecha de que uno de sus integrantes sea cancerígeno, según informa la web de la BBC.

MÁS INFORMACIÓN

Los aditivos ‘cancerígenos’
Los aditivos alimentarios agravan la hiperactividad infantil
El producto en cuestión es el 4-metilimidazol (abreviado como 4-MEI), un colorante que se utiliza para dar el aspecto de caramelo (y que de hecho se produce naturalmente en la cocción de algunos alimentos). Y la alarma ha surgido porque el Estado de California lo ha incluido en la lista de posibles cancerígenos después de un ensayo en ratas. De hecho, según la BBC, las compañías ya han empezado a cambiar su composición en este Estado. Y ello a pesar de que laAgencia del Medicamento estadounidense (FDA) calcula que de acuerdo con ese ensayo una persona debería tomar mil latas diarias de refresco para notar el efecto adverso. La Agencia Europea de Seguridad Alimentaria (EFSA) evaluó el año pasado este producto, y concluyó que no había datos para determinar que era carcinogénico.


Coca-Cola

  • California ha dictaminado que contienen un colorante cancerígeno en ratas
  • La Agencia Europea de Seguridad Alimentaria considera que faltan ensayos

Diario El país http://sociedad.elpais.com

Mejor prevenir. Y si es con un producto cuyo único cometido es dar color, mejor. Es lo que han pensado los fabricantes de bebidas Coca-cola y Pepsi, que han decidido cambiar la composición de sus productos ante la sospecha de que uno de sus integrantes sea cancerígeno, según informa la web de la BBC.

El producto en cuestión es el 4-metilimidazol (abreviado como 4-MEI), un colorante que se utiliza para dar el aspecto de caramelo (y que de hecho se produce naturalmente en la cocción de algunos alimentos). Y la alarma ha surgido porque el Estado de California lo ha incluido en la lista de posibles cancerígenos después de un ensayo en ratas. De hecho, según la BBC, las compañías ya han empezado a cambiar su composición en este Estado. Y ello a pesar de que laAgencia del Medicamento estadounidense (FDA) calcula que de acuerdo con ese ensayo una persona debería tomar mil latas diarias de refresco para notar el efecto adverso. La Agencia Europea de Seguridad Alimentaria (EFSA) evaluó el año pasado este producto, y concluyó que no había datos para determinar que era carcinogénico.

Un portavoz de Coca-cola en España ha declarado que el producto no es un ingrediente, sino que es “un residuo que se produce en el proceso de caramelización”. Y que no se encuentra solo en las bebidas. “Hay más en una tostada”, dice, o en muchos alimentos que se tuestan o se someten al fuego.”De hecho, está considerado un 2B en la lista de cancerígenos de la OMS”, lo que implica que es solo un “posible” carcinogénico, indica el portavoz. Leer más “Coca-cola y Pepsi cambian su composición por un posible cancerígeno”

FDA Approves New Suppliers to Ease Cancer Drug Shortages

“We have made real progress … We believe that (suppliers) will be able to meet the demands of patients in the U.S. market” for the two drugs indefinitely, FDA Dr. Commissioner Margaret A. Hamburg told The Associated Press in an exclusive interview. “It’s a huge relief for us.”

The FDA increasingly has been able to prevent drug shortages, mainly due to a sixfold increase in manufacturers voluntarily notifying the FDA when they anticipate shortages, Hamburg said.

Thanks to such notice, the agency prevented 195 drug shortages in 2011, mostly late in the year after President Obama issued an executive order giving FDA additional powers to address the shortages. Between that order on Oct. 31 and this week, the agency has prevented a total of 114 drug shortages.

Hamburg said that when FDA’s much-expanded drug shortages team is notified about impending shortages and contacts other manufacturers, those companies have been “very responsive” as FDA worked with them on finding ways to boost production.

In the latest case, the FDA said it has temporarily allowed importation of an alternative to Doxil called Lipodox, made by Sun Pharma Global FZE. The Indian drugmaker is already known to the agency, and its factory and the production line for Lipodox have been inspected.


Scimat / Getty Images

SCIMAT / GETTY IMAGES
The FDA approved another supplier for a preservative-free version of methotrexate, a crucial drug for children with a type of leukemia called ALL and for high-dose treatment of bone cancer.

Federal regulators said Tuesday that they’ve approved new suppliers for two crucial cancer drugs, easing critical shortages — at least for the time being — that have left patients and parents frightened about missing life-saving treatments.

The news brings a light at the end of the tunnel for some patients, but not for thousands of others, given that there are currently 283 separate drugs in short supply or totally unavailable in this country.

On Tuesday, the Food and Drug Administration said it will temporarily allow importation of a replacement drug for Doxil, a drug for ovarian and other cancers that hasn’t been available for new patients for months.

The agency also has approved another supplier for a preservative-free version of methotrexate, a crucial drug for children with a type of leukemia called ALL and for high-dose treatment of bone cancer. The version with preservatives can be toxic or cause paralysis in children and other patients getting the drug either via injections into spinal cord fluid or at very high doses.

The FDA also has approved the release of a batch manufactured by Ben Venue Laboratories Inc., shortly before it closed several factories at its complex in Bedford, Ohio, due to serious quality problems. That closing is what turned the on-again, off-again methotrexate shortage that began in late 2008 into a crisis almost overnight, with fears that patients would begin missing treatments as soon as the end of this month. Leer más “FDA Approves New Suppliers to Ease Cancer Drug Shortages”

Whither Qnexa? A Brief History of Diet Pills and the FDA

To address those worries, Qnexa’s maker, Vivus Inc., had suggested approval of drug only for use in men and in women of non-childbearing age. That type of labeling work-around didn’t satisfy the FDA, however, and the agency asked the company to figure out a way to prevent pregnant women from using it.

Qnexa is not the first, nor will it be the last weight-loss pill to seek approval from the FDA. The market is ripe for a new drug to help Americans lose weight: “We really go from Weight Watchers to bariatric surgery when it comes to treatment options,” said Joseph Nadglowski, president of the Obesity Action Coalition, a patient advocacy group in Tampa, Fla., in an interview with Bloomberg. “For many, that’s a pretty big gap.”

But the FDA has a spotty history with diet drugs and an ever-rising bar for new weight-loss remedies. Following is a brief history of the diet drug industry’s successes, failures and near misses.

Amphetamines
The original diet drugs date back to the 1950s. Amphetamines worked simply by boosting metabolism all around, driving the body to burn more calories faster. The problem — as with any energy system pushed to its limits — was that cells aren’t made to burn, burn, burn. They eventually burn out, leading to heart problems, chest pains, palpitations, insomnia and other health issues.

Amphetamines, which boost energy and mood, are also addictive, since they tap into the brain’s reward system. After their potential for misuse emerged, U.S. and European officials banned most amphetamine-based medications, but the drug is still available, often hidden in South American diet remedies.

Fen-phen and Redux
A new combination of the existing appetite-suppressing drugs fenfluramine and phentermine, fen-phen was all the rage in the mid-1990s, leading to weight loss in hundreds of thousands of Americans. In 1996, after much media attention, the FDA approved a related drug, dexfenfluramine, as Redux, which did the same thing as fen-phen but with fewer side effects. Yet the side effects were still severe: in the summer of 1997, the FDA revealed that 82 patients had developed defects in their heart valves while on fen-phen, and that seven patients had come down with the same condition on Redux. Other patients developed pulmonary hypertension, a sometimes fatal lung condition, and a JAMA study confirmed earlier reports that both fen-phen and Redux caused brain damage in lab animals. After millions of prescriptions written, in 1997 both fenfluramine and Redux were pulled from the market.

Sibutramine (Meridia)
Since amphetamines carried too many risks of addiction and other side effects, researchers began focusing on ways to trick the brain into wanting less food. Sibutramine, approved in 1997, worked on brain chemicals that affect appetite: by blocking the reuptake of neurotransmitters such as norepinephrine and serotonin, the drug could suppress the desire to eat and convince the body that it was full, helping dieters lose 5% to 10% of their body weight in a few months. After studies showed users were at higher risk of developing heart problems and stroke, however, the medication was withdrawn from the market in 2010.

Lorcaserin (Lorqess)
Like sibutramine, lorcaserin focused on altering brain chemicals, specifically serotonin, to convince the body it was full. But an FDA panel recommended in 2010 against approving the drug because of studies in which female rats taking the drug developed a disturbing number of mammary tumors. The panel also asked Lorqess’s maker, Arena, to conduct additional tests on the drug’s effect on users with diabetes and heart disease, conditions that commonly affect those who are overweight.

Contrave


We still don’t have a magic pill for weight loss, and the spotty safety records of diet remedies throughout history show why.

Alexander Ho for TIME

ALEXANDER HO FOR TIME

Will the second time will be the charm for the diet drug Qnexa? The Food and Drug Administration (FDA) is reviewing the data on the weight-loss medication, again — an advisory panel will meet on Wednesday — having rejected the drug for approval once already in 2010.

The agency’s Endocrinologic and Metabolic Drugs Advisory Committee initially voted 10-to-6 against approving Qnexa over concerns that that it could increase heart rate and cause birth defects — concerns the FDA still has the second time around. According to the FDA’s briefing documents, the advisory panel will be asked on Wednesday to consider whether Qnexa’s maker, Vivus Inc., should conduct a clinical trial on cardiovascular risks prior to approval — a move that could significantly delay its reaching the market. Vivus proposes doing the study post-approval.

The key question for the panel isn’t whether Qnexa is effective for weight loss — clinical trials suggest it is, though in the second year of one trial, participants regained some of the weight they had lost in the first year — but whether its potential side effects outweigh its benefits.

Qnexa is a combination of two existing drugs — phentermine, an appetite-suppressing stimulant, and topiramate, an anti-seizure medication that is generally prescribed to control epilepsy but also affects appetite. The latter drug, topiramate, increases the risk of oral clefts, a birth defect, by two to five times when used by pregnant women, according to the latest studies, the FDA said. Leer más “Whither Qnexa? A Brief History of Diet Pills and the FDA”

Científicos descubren un fármaco que invierte los síntomas del Alzheimer

La enfermedad presenta en gran parte el problema de la incapacidad del cuerpo para eliminar la proteína beta amiloide del cerebro, producida de forma natural. En el 2008 fue el doctor Gary Landreth el que descubrió que el principal portador de colesterol en el cerebro, la apolipoproteína E (ApoE), facilitaba la liquidación de la beta amiloide.

Landreth y su equipo decidieron entonces estudiar la eficacia del fármaco para el cáncer en elApoE. El bexaroteno estimula los receptores retinoides, a su vez encargados de controlar las producción de la ApoE, así que se trataba de aumentar los niveles de la proteína en el cerebro y reducir la beta amiloides.

Un estudio que se llevó a cabo con ratones y cuyos resultados no pudieron ser más sorprendentes. El bexaroteno mejoró el déficit de la memoria consiguiendo revertir la propia enfermedad. Cuentan que los niveles de beta amiloide llegaron a reducirse en un 25% manteniendo el efecto durante tres días.


Avatar de Miguel Jorge

  | http://alt1040.com

Un grupo de investigadores estadounidenses de Case Western Reserve University ha publicado hace unas horas un importante avance en la lucha contra el Alzheimer. Un fármaco contra el cáncer que llevaba 10 años en circulación, el bexaroteno, es capaz de revertir rápidamente en ratones el déficit patológico, cognitivo y la memoria causada por la aparición de la enfermedad. Un avance increíble que podría acelerar la obtención de un medicamento contra el trastorno neurodegenerativo.

Los resultados, publicados en la revista Science, apuntan a la posibilidad más que significativa de que el fármaco pueda ayudar a las millones de personas que sufren actualmente la enfermedad. El bexaroteno había sido probado para el tratamiento contra el cáncerdesde hace más de una década. Así que los investigadores trasladaron sus efectos como medicamento para ser utilizado en el Alzheimer con unos resultados más que prometedores. Leer más “Científicos descubren un fármaco que invierte los síntomas del Alzheimer”

Medical Monday: The Power of the Tool Box – 3 Key Tools for Pharma Social Media Success

Recently, the CDC released a new resource to help health communicators utilize social media for communicating health data – the Health Communicator’s Social Media Toolkit. This new tool is a great asset for the public health community to establish a framework for utilizing social media.

Similar to the public health/government agency community, the pharmaceutical industry’s highly regulated nature makes similar “tool boxes” a great way for companies to keep their efforts in line with how they can and should be using social media. Here are three key “tools” that every pharmaceutical marketer should integrate into their tool box…


Recently, the CDC released a new resource to help health communicators utilize social media for communicating health data – the Health Communicator’s Social Media Toolkit. This new tool is a great asset for the public health community to establish a framework for utilizing social media.

Similar to the public health/government agency community, the pharmaceutical industry’s highly regulated nature makes similar “tool boxes” a great way for companies to keep their efforts in line with how they can and should be using social media. Here are three key “tools” that every pharmaceutical marketer should integrate into their tool box… Leer más “Medical Monday: The Power of the Tool Box – 3 Key Tools for Pharma Social Media Success”